Mohamed Toumeh, MD
Nephrology · Rochester, MNNPI 1598920969
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $725 of the $1,164 with a category attached, or 62.3%. Synthes GmbH accounts for 62.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $771 and has fallen 86.1% since, to $107 in 2025.
Across 17 payments — averaging $68.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Synthes GmbH$725
- Mallinckrodt Hospital Products Inc.$111
- GSK$106
- Travere Therapeutics, Inc.$44
- Boehringer Ingelheim$31
- Otsuka Pharmaceutical Development & Commercialization, Inc.$25
- plus $121 from 7 others
What the payments were for
- Travel & lodging$72562%
- Food & beverage$44038%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Synthes GmbH | 2 | $725 |
| Mallinckrodt Hospital Products Inc. | 3 | $111 |
| GSK | 1 | $106 |
| Travere Therapeutics, Inc. | 2 | $44 |
| Boehringer Ingelheim | 1 | $31 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Amgen | 1 | $19 |
| Novartis | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Nxstage Medical, Inc. | 1 | $18 |
| AstraZeneca | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$106
How this compares
$1,164 in reported general payments places this provider in the 80th percentile of 208 nephrology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 13 | $26,627 |
| Potassium Citrate ErPotassium Citrate | 62 | $8,018 |
| Calcitriol | 420 | $6,228 |
| Allopurinol | 198 | $2,177 |
| Labetalol Hcl | 31 | $2,113 |
| Calcium Acetate | 22 | $1,727 |
| Metoprolol Succinate | 63 | $1,352 |
| Bumetanide | 28 | $1,328 |
| Sirolimus | 12 | $1,281 |
| Losartan Potassium | 128 | $1,217 |
| Sevelamer Carbonate | 12 | $1,115 |
| Potassium Chloride | 49 | $1,013 |
| Lisinopril | 94 | $682 |
| Nifedipine ErNifedipine | 27 | $662 |
| Amlodipine Besylate | 69 | $533 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Rochester
- Neera DahlRochester$102K
- Fernando FervenzaRochester$102K
- Nelson LeungRochester$32K
- John LieskeRochester$31K
- Leticia RolonRochester$30K
- Nattawat KlomjitRochester$25K
- Ladan ZandRochester$25K
- Marie HoganRochester$19K
- Kianoush Banaei KashaniRochester$19K
- Aleksandra KuklaRochester$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.